A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers

Christopher Urban; Milan J. Anadkat

doi:10.3978/j.issn.2078-6891.2013.033

A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers

Christopher Urban, Milan J. Anadkat

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Currently there are three targeted therapies approved for the treatment of colorectal cancers. These include the epidermal growth factor receptor (EGFR) inhibitors, cetuximab and panitumumab, and the multikinase inhibitor regorafenib. It is important to understand and recognize the common presentations of cutaneous toxicity that result from these agents to effectively manage symptoms and prevent premature discontinuation of anticancer treatment.

Original language	English
Pages (from-to)	319-327
Number of pages	9
Journal	Journal of Gastrointestinal Oncology
Volume	4
Issue number	3
DOIs	https://doi.org/10.3978/j.issn.2078-6891.2013.033
State	Published - Sep 2013

Keywords

Cetuximab
Panitumumab
Regorafenib

Access to Document

10.3978/j.issn.2078-6891.2013.033

Cite this

@article{3a1d037b504a49a7aea2c9f9e8bfcb41,

title = "A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers",

abstract = "Currently there are three targeted therapies approved for the treatment of colorectal cancers. These include the epidermal growth factor receptor (EGFR) inhibitors, cetuximab and panitumumab, and the multikinase inhibitor regorafenib. It is important to understand and recognize the common presentations of cutaneous toxicity that result from these agents to effectively manage symptoms and prevent premature discontinuation of anticancer treatment.",

keywords = "Cetuximab, Panitumumab, Regorafenib",

author = "Christopher Urban and Anadkat, {Milan J.}",

year = "2013",

month = sep,

doi = "10.3978/j.issn.2078-6891.2013.033",

language = "English",

volume = "4",

pages = "319--327",

journal = "Journal of Gastrointestinal Oncology",

issn = "2078-6891",

number = "3",

}

TY - JOUR

T1 - A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers

AU - Urban, Christopher

AU - Anadkat, Milan J.

PY - 2013/9

Y1 - 2013/9

N2 - Currently there are three targeted therapies approved for the treatment of colorectal cancers. These include the epidermal growth factor receptor (EGFR) inhibitors, cetuximab and panitumumab, and the multikinase inhibitor regorafenib. It is important to understand and recognize the common presentations of cutaneous toxicity that result from these agents to effectively manage symptoms and prevent premature discontinuation of anticancer treatment.

AB - Currently there are three targeted therapies approved for the treatment of colorectal cancers. These include the epidermal growth factor receptor (EGFR) inhibitors, cetuximab and panitumumab, and the multikinase inhibitor regorafenib. It is important to understand and recognize the common presentations of cutaneous toxicity that result from these agents to effectively manage symptoms and prevent premature discontinuation of anticancer treatment.

KW - Cetuximab

KW - Panitumumab

KW - Regorafenib

UR - http://www.scopus.com/inward/record.url?scp=84995804543&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2078-6891.2013.033

DO - 10.3978/j.issn.2078-6891.2013.033

M3 - Review article

AN - SCOPUS:84995804543

SN - 2078-6891

VL - 4

SP - 319

EP - 327

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

IS - 3

ER -

A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this